StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Trading Down 30.4 %
NASDAQ CYCC opened at $1.60 on Wednesday. Cyclacel Pharmaceuticals has a 1-year low of $1.41 and a 1-year high of $13.20. The company has a market capitalization of $2.11 million, a PE ratio of -0.06 and a beta of 0.54. The firm’s fifty day simple moving average is $2.31 and its 200-day simple moving average is $3.85.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million during the quarter. As a group, analysts predict that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
Further Reading
- Five stocks we like better than Cyclacel Pharmaceuticals
- Best Stocks Under $10.00
- Hasbro’s Management Made All the Right Calls This Quarter
- What is the Shanghai Stock Exchange Composite Index?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.